Cargando…
Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression
Capecitabine is an orally administered prodrug of 5-fluouracil (5-FU) and is used in first-line treatment of metastatic colorectal cancer. Studies have demonstrated that polymorphisms in 5-FU related ADME genes are associated with the efficacy of capecitabine. However, the relationship between the p...
Autores principales: | Chen, Qi, Mao, Yong, Meng, Fanyi, Wang, Lei, Zhang, Hongjian, Wang, Weipeng, Hua, Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650342/ https://www.ncbi.nlm.nih.gov/pubmed/29088787 http://dx.doi.org/10.18632/oncotarget.19670 |
Ejemplares similares
-
The rs7911488-T allele promotes the growth and metastasis of colorectal cancer through modulating miR-1307/PRRX1
por: Yang, Man, et al.
Publicado: (2020) -
The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients
por: Mao, Yong, et al.
Publicado: (2017) -
A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients
por: Chen, Qi, et al.
Publicado: (2017) -
The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer
por: Zhou, Yingying, et al.
Publicado: (2015) -
Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
por: Vitello, Stefano, et al.
Publicado: (2020)